EUVIMEDEUVIMED entdecken
Open Access

Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma

Jeng-Shiun DU, Sin-Hua Moi, Yu-Hsuan Hung, Ya-Hui Chang, Shu-Jyuan Chang, Min-Hong Wang, Hui-Ching Wang, Chi-Wen Luo, Yu-Ci Yang, Li-Tzong Chen, Mei-Ren Pan

Cancer Genomics - Proteomics · 2026-07 · 23 (4) · 714-729

DOI: 10.21873/cgp.20598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, online erschienen am 29.06.2026. Verfasst von Jeng-Shiun DU und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Deoxycytidine, Cholangiocarcinoma, Bile Duct Neoplasms, Biomarkers, Tumor. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineCholangiocarcinomaBile Duct NeoplasmsBiomarkers, TumorHistone-Lysine N-MethyltransferaseAntimetabolites, AntineoplasticMethyltransferasesHumansGemcitabineGene Expression ProfilingCell Line, TumorFemaleGene Expression Regulation, NeoplasticMaleCell Proliferation

Stichwörter der Autor:innen

CholangiocarcinomaDOT1Lbioinformaticsgemcitabinetranscriptomics

Substanzen

DeoxycytidineGemcitabineBiomarkers, TumorDOT1L protein, humanHistone-Lysine N-MethyltransferaseAntimetabolites, AntineoplasticMethyltransferases

Autor:innen und Institutionen

  • Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
  • Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
  • Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
  • Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
  • Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.; 1025017@kmuh.org.tw 1095056@kmuh.org.tw.
  • Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.; 1025017@kmuh.org.tw 1095056@kmuh.org.tw.

Zitieren

APA

DU, J. S., Moi, S. H., Hung, Y. H., Chang, Y. H., Chang, S. J., Wang, M. H., Wang, H. C., Luo, C. W., Yang, Y. C., Chen, L. T., & Pan, M. R. (2026). Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma. Cancer Genomics - Proteomics, 23(4), 714-729. https://doi.org/10.21873/cgp.20598

Vancouver

DU JS, Moi SH, Hung YH, Chang YH, Chang SJ, Wang MH, et al. Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma. Cancer Genomics - Proteomics. 2026;23(4):714-729. doi:10.21873/cgp.20598

BibTeX
@article{DU2026,
  author = {DU, Jeng-Shiun and Moi, Sin-Hua and Hung, Yu-Hsuan and Chang, Ya-Hui and Chang, Shu-Jyuan and Wang, Min-Hong and Wang, Hui-Ching and Luo, Chi-Wen and Yang, Yu-Ci and Chen, Li-Tzong and Pan, Mei-Ren},
  title = {Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma},
  journal = {Cancer Genomics - Proteomics},
  year = {2026},
  volume = {23},
  number = {4},
  pages = {714--729},
  doi = {10.21873/cgp.20598}
}
Kostenlos starten →